Cargando…

New Insights into the Management of Hypertension and Cardiovascular Risk with Angiotensin Receptor Blockers: Observational Studies Help Us?

Post-marketing observational studies are valuable for establishing the real-world effectiveness of treatment regimens in routine clinical practice as they typically monitor a diverse population of patients over many months. This article reviews recent observational studies of angiotensin receptor bl...

Descripción completa

Detalles Bibliográficos
Autor principal:	Goudev, Assen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021208/ https://www.ncbi.nlm.nih.gov/pubmed/24847388 http://dx.doi.org/10.2174/1874192401408010035

Ejemplares similares

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study
por: Goudev, Assen, et al.
Publicado: (2012)

Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
por: Ram, C Venkata S
Publicado: (2011)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations
por: Gallo, Giovanna, et al.
Publicado: (2022)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension
por: van Sloten, Thomas T, et al.
Publicado: (2022)

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
por: Farsang, Csaba
Publicado: (2011)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines
por: Alcocer, Luis Antonio, et al.
Publicado: (2023)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia—A Systematic Review
por: D’Silva, Elvira, et al.
Publicado: (2022)

The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy
por: Kostourou, Danai-Thomais, et al.
Publicado: (2022)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022)

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?
por: Nieradko-Iwanicka, Barbara
Publicado: (2018)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
por: Khera, Rohan, et al.
Publicado: (2021)

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
por: Baumhäkel, Magnus, et al.
Publicado: (2011)

Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?
por: Fuchs, Flávio Danni, et al.
Publicado: (2015)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021)

Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data
por: Setoguchi, Soko, et al.
Publicado: (2011)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
por: Khera, Rohan, et al.
Publicado: (2020)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up
por: Jeong, Han Saem, et al.
Publicado: (2021)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021)

Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans
por: Derington, Catherine G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t0bjqip65tqad6lukg0bb30vno